玻璃体腔注射雷珠单抗与激光光凝治疗早产儿视网膜病变的比较
该回顾性病例系列纳入165例婴儿共314眼I型早产儿视网膜病变(ROP),分别接受激光光凝(161眼)或玻璃体腔注射雷珠单抗0.25 mg/0.025 mL(153眼)。两组需额外治疗的复发率无显著差异(13.7% vs 9.8%,p=0.196),但激光组视网膜脱离(8 vs 1,p=0.037)和黄斑牵拉(7 vs 1,p=0.039)更多;雷珠单抗组95.6%视网膜完全血管化。
要点
- 雷珠单抗与激光光凝治疗I型ROP的复发率无显著差异。
- 激光组视网膜脱离和黄斑牵拉发生率显著高于雷珠单抗组。
- 雷珠单抗组95.6%患眼视网膜完全血管化,未报告全身或神经发育不良事件。
核心结论
- 玻璃体腔注射雷珠单抗治疗ROP的疗效与激光光凝相似,但视网膜脱离和黄斑牵拉等手术并发症更少。
研究设计与样本
- 161眼接受激光光凝,153眼接受玻璃体腔注射雷珠单抗0.25 mg/0.025 mL。
主要发现
- 平均随访36.3±31.9个月,激光组22眼(13.7%)、雷珠单抗组15眼(9.8%)复发需进一步干预(p=0.196)。
- 视网膜脱离在激光组8眼、雷珠单抗组1眼(p=0.037);黄斑牵拉分别为7眼和1眼(p=0.039)。
- 雷珠单抗组95.6%患眼视网膜完全血管化,未报告全身或神经发育不良事件。
- 多因素分析显示出生体重(OR 0.993,p=0.023)和更高ROP分期(OR 11.222,p=0.008)影响主要并发症发生率。
关键数值与推荐
- 复发性需额外治疗:激光组13.7%(22/161眼),雷珠单抗组9.8%(15/153眼),p=0.196。
- 视网膜脱离:激光组8眼 vs 雷珠单抗组1眼,p=0.037。
- 黄斑牵拉:激光组7眼 vs 雷珠单抗组1眼,p=0.039。
- 雷珠单抗组95.6%患眼视网膜完全血管化。
临床怎么用
- 对I型ROP,玻璃体腔注射雷珠单抗可作为激光光凝的替代方案,疗效相似且手术并发症更少。
- 出生体重较低和ROP分期较高者主要并发症风险增加,需加强随访。
局限性
- 回顾性病例系列设计,非随机对照,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To compare the efficacy, anatomical outcomes and complications of intravitreal ranibizumab with those of laser photocoagulation for retinopathy of prematurity (ROP). METHODS: This is a retrospective case series of 314 eyes from 165 infants diagnosed with type I ROP and treated with either laser photocoagulation (161 eyes) or intravitreal ranibizumab (0.25 mg/0.025 mL) injection (153 eyes) between January 2006 and December 2016 in a tertiary referral-based hospital. The main outcome was the rate of recurrence requiring additional treatment. Secondary outcomes included the incidence of major complications and final refractive error. RESULTS: The mean follow-up was 36.3±31.9 months. Recurrences requiring further intervention were noted in 22 (13.7%) laser-treated and 15 (9.8%) ranibizumab-treated eyes (p=0.196). Retinal detachment (8 vs 1, p=0.037) and macular dragging (7 vs 1, p=0.039) were observed in the laser-treated and injection-treated groups, respectively, but no systemic or neurodevelopmental adverse events were reported. In the ranibizumab group, 95.6% showed fully vascularised retinas. Multivariate analyses revealed that birth weight (OR 0.993, p=0.023) and higher ROP stage (OR 11.222, p=0.008) influenced the incidence of major complications. CONCLUSION: Intravitreal ranibizumab for ROP appears to achieve similar therapeutic effects than did laser photocoagulation, but with fewer surgical complications such as retinal detachment or macular dragging.
引用
- Kang HG, Choi EY, Byeon SH, et al. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety. Br J Ophthalmol. 2018. PMID: 30514709. doi:10.1136/bjophthalmol-2018-312272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。